Impact BioMedical (IBO)
Commercializes health-and-wellness patents and Celios air-purification products.
Something off on this page? Send us feedback.
Sells Celios portable air-purification products online and through distributors while seeking license, milestone and royalty income from a health-and-wellness patent portfolio. Development, manufacturing, regulatory work and commercial execution depend on outside partners.
Develops and patents health and wellness technologies, then commercializes them through licenses, co-development arrangements and joint ventures. Its current retail business sells Celios portable air-purification products online and through third-party distributors. The broader portfolio includes Linebacker small-molecule compounds, Equivir and Equivir-G polyphenol blends, Laetose sugar-and-inositol formulations, and Functional Fragrance Formulation botanical products.
Licenses for Linebacker and Equivir grant worldwide rights to ProPhase Labs, while Laetose and Functional Fragrance Formulation remain available for partnering. Product control on Celios transfers at shipment or delivery, whereas license economics can comprise upfront fees, milestones and royalties. Development, regulatory, manufacturing and commercialization depend on outside research organizations and partners; the business has no internal clinical-supply manufacturing capability or later-stage clinical-trial experience.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.0K · Total debt $0 · Total assets $16.7M · Shareholders' equity $10.8M
- Revenue
- $3.0K
- Operating income
- −$702.0K
- Net income
- −$699.0K
No dividends on record.
| Institutions | 3.56% | 3.83M shares | |
|---|---|---|---|
| 19 holders · as of Jun 30, 2026 | |||
| Other | 96.44% | 103.99M shares | |
| remainder | |||
107.82M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Geode Capital Management, LLCInstitution | 1.10% | 1.19M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.75% | 808,689 | as of Jun 30, 2026 |
State Street CorpInstitution | 0.56% | 607,897 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.55% | 589,428 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.24% | 259,946 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Unilever (ADR)
Blueair is a global home air-filtration rival.
- Ingredion
ASTRAEA allulose rivals in reduced-sugar ingredients.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Impact BioMedical | $0.5499 | −1.04% | $59.9M | — | — | 1,711.9 | −41.4% |
| Unilever (ADR) | $62.78 | +0.97% | $133.93B | 21.1 | — | 2.5 | −17.9% |
| Ingredion | $97.78 | +0.77% | $6.12B | 10.6 | 8.8 | 0.8 | +0.9% |
| Median | 15.8 | 8.8 | 1.7 | −8.5% |